Franz-Werner Haas (Christoph Schmidt/picture-alliance/dpa/AP Images)
July 20, 2023 05:00 AM EDT
Deals
Bioregnum

A small Swiss biotech tack­les a huge glob­al health is­sue with a hand­off from GSK. But can it make any mon­ey from it?

Dur­ing the glob­al pan­dem­ic, we got a good look at how a new tech­nol­o­gy can trans­form the vac­cines mar­ket and earn bil­lions of dol­lars in …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times